

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Michael Philip Cohen et al.  
SERIAL NUMBER: 10/509,770 EXAMINER: Chang, Celia C.  
FILING DATE: September 28, 2004 ART UNIT: 1625  
TITLE: PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT OF SUBSTANCE OF THE INTERVIEW**

This paper is in response to the Examiner-Initiated Interview Summary (PTO Form PTOL-413), which was transmitted on May 23, 2008 in the above-identified application. Although Part III of the Interview Summary does not indicate whether a substance of the interview is required, pursuant to 37 C.F.R. § 1.133, Applicants hereby submit a Statement of the Substance of the telephone interview held on May 7, 2008 between Ivor R. Elrifi and Examiner Celia Chang.

During this interview, claims 13, 27-45, and 59-61 were discussed. The Examiner will issue an Examiner's Amendment. Specifically, the amendment will insert the term "an effective amount of" after the word "comprising" in claims 55 and 59-61. In claim 13, the term "or prevention" will be deleted and after the word "mammal", the term "in need thereof" will be inserted. Claims 27-45 are canceled.

### CONCLUSION

Applicants believe that no fees are due in connection with the filing of this paper. However, the Commissioner is hereby authorized to charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 34251-502 NATL.

If there are any questions regarding this Statement, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

*for: Jennifer Polach*  
Ivor R. Elrifi, Reg. No. 39,529 *Reg # 52,922*  
Attorney for Applicants  
c/o MINTZ, LEVIN  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623

Dated: June 25, 2008